Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 16/20 | 0.68 |
| ▸ | NPY1R | P25929 | 10/20 | 0.68 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.68 |
| ▸ | NPY2R | P49146 | 6/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29641098 | 1.00 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29641056 | 1.00 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL8975655 | 0.97 | NPY4R (0.67) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL8975469 | 0.96 | NPY4R (0.73) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29483774 | 0.96 | NPY4R (0.73) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29461992 | 0.96 | NPY4R (0.63) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL22133073 | 0.95 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29641130 | 0.95 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29641040 | 0.95 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29641095 | 0.95 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220372172-A1 | METHOD AND CARRIER COMPLEXES FOR DELIVERING MOLECULES TO CELLS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2022-11-24 | — | — | US | claimed |
| EP-4711005-A2 | METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH | Stealth BioTherapeutics Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260061023-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BARTH SYNDROME | STEALTH BIOTHERAPEUTICS INC. (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260062752-A1 | METHODS AND COMPOSITIONS FOR DETECTING AND DIAGNOSING DISEASES AND CONDITIONS | STEALTH BIOTHERAPEUTICS INC. (US) | 2026-03-05 | — | — | US | disclosed |
| US-12527770-B2 | Methods of managing pain using dexmedetomidine transdermal delivery devices | TEIKOKU PHARMA USA, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250319152-A1 | METHODS FOR THE PREVENTION OR TREATMENT OF LEFT VENTRICLE REMODELING | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250276116-A1 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | TUFTS MEDICAL CENTER, INC. | 2025-09-04 | — | — | US | disclosed |
| US-20250263433-A1 | METHODS FOR REDUCING CD36 EXPRESSION | CORNELL RESEARCH FOUNDATION, INC. (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250262269-A1 | METHODS FOR PERFORMING A CORONARY ARTERY BYPASS GRAFT PROCEDURE | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250255929-A1 | METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-08-14 | — | — | US | disclosed |
| EP-3698832-B1 | METHODS AND DEVICES FOR SMOKING URGE RELIEF | FONTEM HOLDINGS 1 BV (NL) | 2022-07-13 | — | — | EP | disclosed |
| US-11376304-B2 | Methods and compositions for the prevention and treatment of disease | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-11366104-B2 | Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-06-21 | — | — | US | disclosed |
| EP-4005582-A1 | TREATMENT OF LEFT VENTRICULAR REMODELING | Stealth BioTherapeutics Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-4000690-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | Stealth BioTherapeutics Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11312993-B2 | Methods and compositions for detecting and diagnosing diseases and conditions | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11266709-B2 | Methods for the regulation of matrix metalloproteinase expression | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-03-08 | — | — | US | disclosed |
| EP-0350221-B1 | Dermorphin analogs, their methods of preparation, pharmaceutical compositions, and methods of therapeutic treatment using the same | ASTRA AB (SE) | 1996-04-17 | — | — | EP | disclosed |
| US-5312899-A | Dermorphin analogs | BIOCHEM PHARMA, INC. (CA) | 1994-05-17 | — | — | US | disclosed |
| EP-0350221-A2 | Dermorphin analogs, their methods of preparation, pharmaceutical compositions, and methods of therapeutic treatment using the same | Astra Aktiebolag (SE) | 1990-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260061023-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BARTH SYNDROME | ARG2, ARGLU1, BCAT1 | NPY4R 2600/4885NPY1R 872/4885NPY5R 1341/4885 |
| US-20250255929-A1 | METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH | TNNI3, TNNT2, FABP3 | NPY4R 2454/4885NPY1R 1553/4885NPY5R 2704/4885 |
| US-12527770-B2 | Methods of managing pain using dexmedetomidine transdermal delivery devices | OPRD1, OPRK1, OPRM1 | NPY4R 448/4885NPY1R 252/4885NPY5R 244/4885 |
| US-20250319152-A1 | METHODS FOR THE PREVENTION OR TREATMENT OF LEFT VENTRICLE REMODELING | ARG2, TNNT2, MYLK2 | NPY4R 700/4885NPY1R 913/4885NPY5R 680/4885 |
| US-20260062752-A1 | METHODS AND COMPOSITIONS FOR DETECTING AND DIAGNOSING DISEASES AND CONDITIONS | ARG2, MTPN, TNNT2 | NPY4R 3734/4885NPY1R 3368/4885NPY5R 3526/4885 |
| US-11376304-B2 | Methods and compositions for the prevention and treatment of disease | COL2A1, ALPI, COL14A1 | NPY4R 223/4885NPY1R 735/4885NPY5R 484/4885 |
| US-20250262269-A1 | METHODS FOR PERFORMING A CORONARY ARTERY BYPASS GRAFT PROCEDURE | RNPEP, TNNI3, BDKRB1 | NPY4R 350/4885NPY1R 209/4885NPY5R 173/4885 |
| US-20250276116-A1 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | TNNI3, TNNT2, MB | NPY4R 4783/4885NPY1R 4818/4885NPY5R 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.